Aptamer Inhibiting Factor D for Dry AMD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments are lacking for dry age-related macular degeneration (AMD) and geographic atrophy, with no FDA-approved therapies available, and existing treatments for wet AMD do not address the underlying issues of dry AMD.
Innovation Solution
A pharmaceutical composition comprising a therapeutically effective amount of an aptamer that inhibits the function associated with complement Factor D, specifically binding to its active site, catalytic cleft, or exosite, is administered intravitreally or topically to treat ocular diseases such as dry AMD and geographic atrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for wet AMD are used, then wet AMD symptoms are addressed, but dry AMD and geographic atrophy remain untreated
Solution Approach 1:
The patent segments the complement pathway into distinct targets: Factor D inhibition for dry AMD and geographic atrophy, while other treatments address wet AMD. This segmentation allows specialized treatment for each disease form without interference from cross-reactivity
Solution Approach 2:
The aptamer serves as an intermediary molecule that specifically binds to Factor D, blocking its interaction with C3b and preventing alternative complement pathway activation. This intermediary approach provides targeted inhibition without affecting other complement factors or pathways
2Reliability
If complement pathway inhibition is implemented, then alternative pathway activation is blocked, but potential off-target effects on other pathways may occur
Solution Approach 1:
The aptamer exhibits local quality through its highly specific binding to Factor D's catalytic cleft or exosite. This localized binding ensures inhibition is confined to the alternative complement pathway while leaving classical and lectin pathways intact, preventing off-target effects
Solution Approach 2:
The patent utilizes parameter changes in the aptamer's binding characteristics, achieving high affinity (low Kd values) and high specificity for Factor D. These parameter optimizations ensure potent inhibition of the alternative pathway while maintaining selectivity against other complement factors
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamer effectively inhibits the activity of complement Factor D, providing a potential treatment for dry AMD and geographic atrophy by targeting the alternative complement pathway, which is implicated in the pathogenesis of these conditions.
Implementation Method 1
the aptamer binds to complement Factor D... the aptamer binds to a catalytic cleft of complement Factor D... the aptamer binds to an active site, catalytic cleft, or exosite of complement Factor D
Data Source
AI summary
The application discloses methods and compositions for the inhibition of the alternative complement pathway. The methods and compositions involve the use of aptamers for inhibiting complement Factor D. The application further provides anti-Factor D aptamers for the treatment of dry age-related macular degeneration, geographic atrophy, wet age-related macular degeneration or Stargardt disease.